BA
PTCT icon

Bridgewater Associates’s PTC Therapeutics PTCT Stock Holding History

Bridgewater Associates’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,229
Closed -$1.23M – 1180
2025
Q4 		$1.23M Buy
16,229
+4,291
+36% +$312K ﹤0.01% 851
2025
Q3 		$733K Buy
+11,938
New +$622K ﹤0.01% 881

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Bridgewater Associates's PTCT Position: Q1 2026 in Review

Bridgewater Associates sold out of PTC Therapeutics (PTCT) in Q1 2026, closing a stake of 16,229 shares — an estimated $1.23M sold.

Bridgewater Associates first reported a position in PTCT in Q3 2025 and held it in 2 quarters. The position peaked at $1.23M in Q4 2025. 352 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • Bridgewater Associates reported no remaining PTC Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Bridgewater Associates sold 16,229 PTC Therapeutics shares in Q1 2026, an estimated $1.23M.
  • Bridgewater Associates first reported a position in PTC Therapeutics in Q3 2025 and held it in 2 quarters.
  • Bridgewater Associates's PTC Therapeutics position peaked at $1.23M in Q4 2025.
  • 352 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on Bridgewater Associates's 13F filing for Q1 2026, filed 15 May 2026.